HCPCS code J7613: Albuterol unit dose billing guide

Key takeaways

HCPCS code J7613 covers albuterol sulfate inhalation solution, FDA-approved final product, administered via DME nebulizer, billed per 1 mg unit dose.

Billing unit is per 1 mg of albuterol. Multiply the vial volume (mL) by the concentration percentage, then divide by 100 to calculate the number of units.

J7613 covers only FDA-approved final products, not compounded preparations. Using J7611, the concentrated form, instead of J7613 for a ready-to-use vial is a common denial trigger.

Pabau’s claims management tools flag missing claim data before submission and track claim status through payment, helping practices submit cleaner claims.

HCPCS code J7613 is the designated code for FDA-approved albuterol inhalation solution administered through durable medical equipment (DME) nebulizers, according to CMS. It is billed on a per-1-mg unit dose basis for Medicare Part B claims. Most claim denials trace back to miscalculating the number of units or selecting the wrong albuterol HCPCS code.

This reference covers J7613’s definition, unit dose calculation by concentration, Medicare and Medicaid coverage rules, required documentation, and ICD-10 support codes. It also covers the J7613 vs J7611 distinction that trips up even experienced coders.

HCPCS code J7613: Definition and description

HCPCS code J7613 describes albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 1 mg. It falls under HCPCS Level II, the system CMS maintains for drugs and supplies not covered by CPT. The code classifies the nebulized delivery of a short-acting beta-2 agonist used to treat bronchospasm in asthma, COPD, and related conditions.

Three elements of this description carry billing implications. “FDA-approved final product” means the drug must be a finished commercially manufactured product, not a compounded preparation. “Administered through DME” means the patient or caregiver uses a supplier-provided nebulizer. “Per 1 mg” is the billing unit, meaning every milligram of albuterol dispensed generates one unit on the claim.

J7613 code details at a glance

Albuterol concentrations covered under J7613

Albuterol sulfate inhalation solution comes in three standard concentrations, all covered under HCPCS code J7613 when dispensed as an FDA-approved unit dose vial. The concentration determines how many milligrams of albuterol are in each vial, which directly affects the number of units billed per treatment.

North Carolina DHHS billing guidance confirms these three concentrations as covered under J7613. Billers should note that rounding rules apply: quantities below 0.5 round down to zero, while 0.5 and above round up to the next whole unit. A 0.021% vial containing 0.63 mg rounds to 1 unit billed. Always verify rounding methodology with your MAC, as regional guidance can differ.

How to calculate albuterol units for billing

Unit dose calculation for J7613 follows a straightforward formula: multiply the vial volume in milliliters by the concentration percentage, then divide by 100. The result is the number of milligrams of albuterol, which equals the number of J7613 units to bill. Understanding this prevents both underbilling and the overcounting that triggers audits.

Formula: Volume (mL) x Concentration (%) / 100 = Albuterol (mg) = J7613 units

Three worked examples using the most common vial sizes:

• 0.021% / 3 mL vial: 0.021 g/100 mL × 3 mL = 0.00063 g = 0.63 mg. Bill 1 unit.
• 0.042% / 3 mL vial: 0.042 g/100 mL × 3 mL = 0.00126 g, labeled by the manufacturer as 1.25 mg. Bill 1 unit.
• 0.083% / 3 mL vial: 0.083 g/100 mL × 3 mL = 0.00249 g, typically cited as 2.5 mg. Bill 3 units.

CGS Medicare provides a nebulizer medication calculator specifically for albuterol J-codes that billers can use to verify unit counts before submitting claims. When a patient receives multiple treatments per day, multiply the per-treatment unit count by the number of treatments to get the total daily units. Verify against the physician’s written order to confirm the dispensed quantity matches what was prescribed.

Accurate medical billing for nebulizer drugs like albuterol depends on linking calculated units directly to the dispensed vial’s NDC number on the claim. This NDC-to-unit crosswalk is a Medicare requirement, not optional documentation.

Medicare coverage and reimbursement

HCPCS code J7613 is covered under Medicare Part B as a DMEPOS item. The claim goes through the patient’s DME supplier rather than the treating physician. CMS Policy Article A52466 governs nebulizer medication coverage, establishing which drugs qualify and what documentation suppliers must maintain. Suppliers must hold active DMEPOS accreditation to bill J7613 to Medicare.

Coverage requires three forms of documentation on file:

• Medical necessity documentation showing the patient has a condition treated with nebulized albuterol.
• A valid written order from the treating physician.
• Proof of delivery to the beneficiary.

Insurance eligibility verification before dispensing is essential. The drug claim will likely deny if the patient’s Medicare Part B coverage has lapsed. It will also deny if the nebulizer equipment is not on file as medically necessary.

J7613 fee schedule and pricing

Medicare reimbursement rates for J7613 are set through the CMS Physician Fee Schedule lookup and the DMEPOS fee schedule, updated annually. Rates vary by Medicare Administrative Contractor (MAC) jurisdiction and are adjusted by geographic locality. As a result, a supplier in jurisdiction C (CGS Medicare) may receive a different allowable than one in another jurisdiction.

Because rates change each January 1 and vary by region, this guide does not publish a specific dollar rate. Always verify the current allowable through the CMS DMEPOS fee schedule for your MAC jurisdiction before setting patient cost estimates. Electronic remittance advice (ERA) from Medicare will show the paid amount and any adjustments after claim adjudication.

Medicaid billing guidelines

Medicaid coverage for J7613 follows state-specific rules, so billing practices that work in one state may not apply in another. North Carolina Medicaid, for example, covers albuterol sulfate inhalation solution under J7613 at 0.021%, 0.042%, and 0.083% concentrations. Prior authorization applies to certain coverage scenarios.

Billers working across multiple states should treat Medicaid J7613 billing as state-by-state research. Key variables include:

• Prior authorization: Some states require PA for ongoing nebulizer drug supplies; others allow a blanket medical necessity determination.
• Fee schedules: State Medicaid fee schedules for J7613 are independent of Medicare’s DMEPOS rates.
• Documentation: Most states mirror CMS documentation requirements, but some add state-specific forms or certificate of medical necessity variants.
• Formulary restrictions: Certain state Medicaid programs have preferred drug lists that affect which NDC products they reimburse under J7613.

Check your state Medicaid agency’s provider billing manual for the current J7613 rules before submitting. For practices managing revenue cycle management across multiple payers, maintaining separate Medicaid billing workflows by state reduces denial risk significantly.

Documentation requirements for nebulizer claims

CMS Policy Article A52466 establishes the documentation suppliers must keep on file to support J7613 claims. Missing even one of these elements is a common reason Medicare auditors recoup payments on nebulizer drug claims. Maintaining billing compliance for DME drug claims means keeping these records current and readily accessible.

• Written order: A signed order from the treating physician specifying the drug, concentration, dosing frequency, and duration of therapy. The order must be in the supplier’s file before the drug is dispensed.
• Medical necessity documentation: Clinical records showing the diagnosis that justifies nebulized albuterol, such as pulmonary function test results, office visit notes, or hospital discharge summary.
• Proof of delivery: A delivery confirmation signed by the patient or their representative, showing the drug was received. Electronic proof of delivery systems satisfy this requirement.
• NDC reporting: The National Drug Code for the specific albuterol product dispensed must appear on the claim along with the quantity supplied.
• Certificate of medical necessity (CMN): For ongoing nebulizer drug therapy, CMS may require a CMN from the treating physician. This applies at initial dispensing and at periodic recertification.

A superbill or structured dispensing record that captures all of these elements at the point of service reduces the documentation chase that often delays claims. HIPAA transaction standards govern how this information is transmitted on 837P claims, making data accuracy at entry critical.

Cut J7613 claim errors with smarter billing workflows

Pabau’s claims management tools flag missing data before submission and track every J7613 claim from submission through payment. See how it works.

Book a demo

ICD-10 diagnosis codes that support albuterol billing

Every J7613 claim must be linked to at least one ICD-10-CM diagnosis code that establishes medical necessity for nebulized albuterol. Medicare and Medicaid use these codes to confirm the drug is clinically appropriate. The table below lists the most commonly accepted diagnosis codes for J7613 claims. Payer-specific Local Coverage Determinations (LCDs) may define the complete covered list for your MAC.

Always confirm covered diagnosis codes against your MAC’s LCD for nebulizers before submitting. Codes not appearing on the LCD covered list are a leading cause of J7613 medical necessity denials. Reviewing the denial management process for nebulizer drug claims helps practices build appeal workflows. This matters when the initial claim is denied despite a valid clinical indication.

J7613 vs J7611: Understanding the difference

HCPCS code J7613 and J7611 both describe FDA-approved albuterol inhalation solutions, but they cover different product forms. Billing the wrong code causes denials that can take weeks to resolve.

The practical rule: use HCPCS code J7613 for a pre-filled, ready-to-use albuterol vial at one of the three standard concentrations. Use HCPCS code J7611 instead when the product is a concentrated albuterol solution that requires dilution before nebulization. Never use J7613 for compounded albuterol preparations, since those fall under separate HCPCS coding rules. Verify the exact J7611 descriptor against the current AAPC HCPCS code lookup before submitting.

Common billing errors to avoid

J7613 denials cluster around a predictable set of mistakes. Most are preventable with the right workflows at the point of dispensing.

• Miscalculating units: Billing 1 unit for a 0.083% vial instead of the correct 3 units, or vice versa. Always apply the volume x concentration formula before submitting.
• Using J7613 for compounded albuterol: J7613 strictly covers FDA-approved final products. Compounded preparations require a different code. Submitting J7613 for a compounded product is a billing error that can trigger a compliance review.
• Confusing J7613 with J7611: The unit dose / concentrated distinction matters to payers. A mismatched code against the NDC on the claim will cause an edit fail at the clearinghouse or a denial from the MAC.
• Missing NDC on the claim: Medicare requires the NDC for each drug billed via a J-code. Submitting J7613 without the corresponding NDC, units, and unit qualifier (F2 for international units, or ML for milliliters) triggers an automatic edit.
• No written order on file before dispensing: Orders obtained after dispensing do not satisfy Medicare’s “in advance” requirement. The order must precede delivery.
• Incorrect or unsupported ICD-10 codes: Submitting a diagnosis code not on the MAC’s LCD covered list for nebulizers results in a medical necessity denial. This happens even when the drug is clinically appropriate.

Tracking denial patterns for J7613 claims through claims management software turns a reactive billing process into a proactive one. When a denial reason code consistently appears against J7613 claims, it signals a systemic workflow problem rather than a one-off error. Understanding what makes a clean claim for nebulizer drugs is the first step toward consistently first-pass approval rates.

NDC numbers and crosswalk requirements

Every J7613 claim submitted to Medicare must include the National Drug Code (NDC) for the specific albuterol product dispensed. The NDC is an 11-digit number that identifies the manufacturer, product, and package size. CMS uses the NDC to verify that the billed J-code matches the dispensed product. This also helps detect substitution between similar products billed under the wrong code.

Common albuterol sulfate inhalation solution NDCs mapping to J7613 include products manufactured by Nephron Pharmaceuticals, Akorn, and other FDA-approved manufacturers. Because NDC numbers are product-specific and pharmaceutical formularies change, this guide does not publish a definitive NDC list. Use the NLM Clinical Table Search API or your wholesaler’s current formulary. Either source shows which NDCs for albuterol inhalation solution currently crosswalk to J7613.

On the claim, report the NDC using qualifier N4 in the appropriate field of the CMS-1500 form or 837P electronic transaction. Include the quantity dispensed in the NDC unit of measure (typically mL) alongside the J7613 unit count. Mismatches between the NDC unit quantity and the billed J7613 units are a top audit trigger for DME drug claims. Reviewing the HIPAA compliance requirements for claim transactions ensures the data fields are submitted correctly.

How Pabau supports nebulizer billing workflows

J7613 billing failures usually happen at three points: unit calculation at dispensing, documentation assembly before submission, and denial follow-up after adjudication. Practice management software like Pabau addresses all three without manual cross-referencing between dispensing records and billing software.

Pabau’s claims management features help practices build structured billing workflows around J-codes. Required fields stay flagged until complete. A J7613 claim cannot go out missing an NDC or carrying a diagnosis code that falls outside the LCD covered list. A single dashboard then tracks the claim’s status from submission through payment.

Practices managing medical billing across multiple payer types benefit from keeping claims alongside the rest of the patient and billing record. Doing so removes the paper chase that makes audits disruptive, and real-time eligibility checks catch a lapsed policy before a claim goes out.

Conclusion

HCPCS code J7613 is a precision instrument. Its three requirements, FDA-approved product, DME administration, and per-1-mg unit billing, are straightforward. Small errors in unit calculation, NDC reporting, or code selection cause denials that take disproportionate time to resolve. Most J7613 billing problems stem from process breakdowns rather than complex coding questions.

Pabau’s denial management and claims submission workflows give practices the structure to catch missing data before claims leave the building. To see how Pabau handles nebulizer drug billing end to end, book a demo.

Continue your research

Need a framework for reducing claim denials across all payer types? Denial management in healthcare covers the most effective workflows for tracking, appealing, and preventing common claim rejections.

Want to understand how clean claims improve first-pass rates? What makes a clean claim explains the data elements and workflow steps that reduce edits and accelerate reimbursement.

Looking for guidance on medical billing compliance requirements? Medical billing compliance outlines the documentation, transaction, and audit requirements practices must meet to stay compliant.

Frequently asked questions